Sinclair IS Pharma Plc PT Raised to GBX 43 (SPH)
Analysts at Nplus1 Brewin boosted their target price on shares of Sinclair IS Pharma Plc (LON:SPH) from GBX 36 ($0.59) to GBX 43 ($0.71) in a research report issued to clients and investors on Thursday, Analyst Ratings Network.com reports. The firm currently has a “buy” rating on the stock. Nplus1 Brewin’s price target would indicate a potential upside of 39.84% from the stock’s previous close.
Shares of Sinclair IS Pharma Plc (LON:SPH) traded down 6.82% during mid-day trading on Thursday, hitting GBX 30.75. The stock had a trading volume of 3,506,671 shares. Sinclair IS Pharma Plc has a 52-week low of GBX 23.15 and a 52-week high of GBX 34.00. The stock’s 50-day moving average is GBX 30.03 and its 200-day moving average is GBX 28.61.
A number of other firms have also recently commented on SPH. Analysts at FinnCap reiterated a “buy” rating on shares of Sinclair IS Pharma Plc in a research note to investors on Thursday. They now have a GBX 48 ($0.79) price target on the stock. Separately, analysts at N+1 Singer raised their price target on shares of Sinclair IS Pharma Plc from GBX 36 ($0.59) to GBX 43 ($0.71) in a research note to investors on Thursday. They now have a “buy” rating on the stock. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Sinclair IS Pharma Plc in a research note to investors on Tuesday, January 7th. They now have a GBX 38 ($0.63) price target on the stock. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of GBX 67.44 ($1.11).
Sinclair IS Pharma plc is a specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through surface technology and delivery systems.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.